One key group includes individuals who arent looking for weight loss but want to support their metabolic health, manage chronic inflammation, or take a proactive approach to disease prevention and longevity
This is an investigational oral medicine for inflammatory bowel diseases (ulcerative colitis and Crohn's disease), a large, multibillion-dollar market where many therapies are administered via subcutaneous injections or intravenously, making an oral option particularly attractive, all else being equal
Retatrutide is the first triple agonistit works on GLP-1, GIP, and glucagon receptors
The pivotal trials tested 0.25mg as the lowest dose, and even that was considered a non-therapeutic escalation dose
Fatigue deepens
13 This would create a highly differentiated product that solves a real-world clinical problem while leveraging a streamlined regulatory path